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were required for DRUG to generate greater gains than FBT. The incremental cost 
of moving from the lowest cost strategy to FBT with the greatest gain was $507 
per additional QALY gained. CONCLUSIONS: All treatment strategies examined 
for urge incontinence provide clinical benefits, are relatively cost effective and 
offer QALYs at a bargain price. Clinicians should be encouraged to screen for and 
actively offer treatment options for urge incontinence in older adults.  
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OBJECTIVES: To assess the cost-effectiveness analyses for refractory overactive 
bladder (OAB). METHODS: A systematic literature review of economic 
evaluations of therapies for OAB was conducted using PubMed. For inclusion, 
studies had to compare two or more OAB treatments including at least one third-
line treatment according to the American Urological Association. Articles were 
excluded if the study population was classified as neurogenic or predominantly 
stress incontinence. RESULTS: The initial search yielded 654 articles. After title 
review, 92 abstracts were identified as potentially eligible articles. Sixty-five 
abstracts were excluded because they did not meet inclusion criteria. Twenty-
seven full-text articles were evaluated, of which 19 studies were excluded for 
lack of third-line treatment and two studies were excluded because OAB was 
classified as neurogenic. Of the six included studies, five were decision models, 
and one was a prospective cohort. Three of the decision models compared 
onabotulinumtoxin A to sacral nerve modulation with one of the models also 
allowing continued anticholinergic use as an additional intervention. One 
decision model compared onabotulinumtoxin A to anticholinergics. The 
remaining decision model compared peripheral tibial nerve stimulation to 
extended-release tolterodine. All of the studies were published recently, between 
2009 and 2011. In four of the studies the perspective was “societal,” and in the 
remaining two it was from the perspectives of government payers. All decision 
analyses were based on direct medical costs and did not include the cost of lost 
productivity. Most of the studies based costs and utility scores on women with 
stress incontinence, not patients with refractory urge incontinence. No studies 
used direct comparative data or long-term evidence from clinical studies to 
evaluate refractory treatments. CONCLUSIONS: Few published economic 
evaluations exist that assess treatments for refractory OAB. Additional studies 
on the effectiveness of refractory OAB treatments are needed to accurately 
assess the cost-effectiveness of these interventions.  
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OBJECTIVES: To evaluate long-term cost-effectiveness of a fixed-dose 
combination (FDC) product comprising 0.5mg dutasteride and 0.4mg tamsulosin 
daily, compared to concomitant administration of both dutasteride (0.5 mg)  
and tamsulosin (0.4 mg) monotherapies for the treatment of symptomatic benign 
prostatic hyperplasia (BPH) in Quebec, Canada. METHODS: Our previously 
reported Markov state transition model was adapted to simulate the costs  
and outcomes associated with patients on either type of combination therapy for 
a 10-year period. As both combination therapies have been shown to be 
bioequivalent, a cost-minimization analysis was conducted from the perspective 
of the Quebec provincial health care system. The model follows a Quebec cohort 
of 312,448 male patients aged ≥50 years, diagnosed with moderate to severe 
symptomatic BPH, similar to the cohort studied in the pivotal 4-year CombAT 
study, which evaluated concomitant therapy of dutasteride and tamsulosin  
in BPH patients at risk of clinical progression. Costs and outcomes  
were discounted at 5% per year. Results are presented in the form of total health 
care costs, including dispensing fees, over a period of 10 years for  
both combination therapies. RESULTS: Over a 10-year period, the use of  
FDC compared with concomitant Dutasteride + Tamsulosin therapy could  
save the Quebec health care payer up to $356.86m over 10 years ($1.995bn for 
FDC vs $2.352bn for concomitant therapy, or $1152/patient) when dispensing fees 
were included, or $140.4m (or $450/patient) without dispensing fees. This cost-
saving is driven by lower wholesale acquisition costs of FDC compared to 
Dutasteride + Tamsulosin administered concomitantly, and the fact that that 
only one prescription is needed when dispensing the new FDC (when 
considering dispensing fees). CONCLUSIONS: The introduction of the FDC in 
Quebec for the treatment of moderate to severe symptomatic BPH patients 
would be expected to yield a cost-savings to the health care system over a 10-
year period.  
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OBJECTIVES: To compare health care costs and utilizations between patients 
with an overactive bladder (OAB) who were adherent to OAB medication versus 
those who were not. METHODS: Adult patients with at least two OAB diagnoses 
and two consecutive OAB prescriptions (tolterodine tartrate, oxybutynin 
chloride/transdermal, trospium chloride, solifenacin succinate, darifenacin 
hydrobromide) between July 1, 2007-December 31, 2010 were selected from the 
MarketScan Commercial and Medicare Supplemental Claims Database. 
Continuous eligibility for 6 months pre- and 12 months post-index date (first 
OAB prescription date), and no prior use of OAB medications during the 6-month 
baseline were required. Adherent (proportion of days covered [PDC] to 
medication ≥0.8) and non-adherent (PDC<0.8) cohorts were defined. Follow-up 
health care costs and utilizations were compared between the cohorts. 
Propensity score matching was used to control baseline differences in age, 
gender, region, comorbidities, costs and utilizations. RESULTS: A total of 45,856 
patients were identified (adherent: N=11,851; non-adherent: N=34,005). Adherent 
patients were older (65.40 vs. 62.50, p<0.0001), more likely to be male (34.01% vs. 
30.59%, p<0.0001), and had higher Charlson Comorbidity Index scores (1.34 vs. 
1.24, p<0.0001). During 1-year follow-up, adherent patients had lower inpatient 
(17.00% vs. 21.32%) and emergency room (ER) visit rates (27.12% vs. 32.21%), lower 
medical costs ($22,608 vs. $26,000), but higher pharmacy costs ($12,382 vs. $7,526) 
than non-adherent patients (all p-values<0.0001). After matching, 11,850 patients 
from each cohort were further analyzed. Adjusted outcomes revealed that 
adherent patients had lower inpatient (17.00% vs. 23.99%) and ER visit rates 
(27.11% vs. 34.24%), translating to lower inpatient costs ($6,453 vs. $9,187, 
p<0.0001). Higher pharmacy costs for adherent patients (all-cause: $12,374 vs. 
$9,011; OAB-related: $2,238 vs. $945, all p<0.0001) were offset by lower medical 
costs (all-cause: $22,553 vs. $27,985; OAB-related: $732 vs. $1,289, all p<0.0001). 
CONCLUSIONS: Higher adherence with OAB medications was associated with 
fewer inpatient and ER visits, higher pharmacy costs, but significant lower 
medical and total costs.  
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OBJECTIVES: Few utility data are available for overactive bladder (OAB) in the 
literature. This study compared utilities derived from a disease-specific 
instrument, OAB-5D, and a generic instrument, EQ-5D, according to severity of 
OAB symptoms and evaluated their sensitivity to change. METHODS: Analyses 
were based on pooled data from three 12-week randomized controlled trials of 
OAB treatments. EQ-5D and OAB-5D were assessed monthly. Time trade-off 
tariffs elicited from UK population were applied to obtain utilities from both 
instruments. Repeated measures linear regression was used to estimate 
differences between EQ-5D and OAB-5D utilities by symptom severity level for 
micturition frequency and incontinence. Variations in utility from baseline to 
week 12 were estimated by symptomatic response (improvement, stable or 
worsening). RESULTS: The sample included 4349 OAB patients. Mean utilities 
were 0.82 (standard deviation: ±0.21) for EQ-5D and 0.86 (±0.09) for OAB-5D.  
The correlation between the two measures was 0.33 (p<0.0001). EQ-5D and OAB-
5D utilities increased as OAB symptoms improved. Utilities were similar between 
instruments for patients with severe symptoms, but OAB-5D utilities  
were significantly greater than EQ-5D utilities for mild cases. Incontinence  
had more impact on both OAB-5D and EQ-5D utilities than micturition 
frequency. Changes from baseline in OAB-5D utility differed significantly 
according to symptomatic response. Changes in EQ-5D utility were not 
significantly associated with changes in micturition frequency and weakly 
associated with changes in incontinence severity among patients with mild 
symptoms at baseline. CONCLUSIONS: This study suggests that EQ-5D and OAB-
5D are sensitive tools to measure differences in efficacy between OAB 
treatments, especially in severe cases. However, EQ-5D may not be as sensitive 
as OAB-5D in measuring differences between treatments in milder cases. A 
limitation of OAB-5D may be that it over estimates utilities in less severe cases 




RESULTS OF A STUDY EVALUATING PATIENT'S PERCEPTION  
REGARDING THEIR ERYTHROPOIESIS STIMULATING AGENT TREATMENT IN  
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OBJECTIVES: Patient’s perception regarding their treatment has a real interest in 
health care, especially in chronic disease. The Percepolis study aims to describe 
patient’s preference regarding their ESA treatment. METHODS: This is a 6-month 
multicenter prospective Non-Interventional Study conducted by 111 French 
nephrologists in 2011. Eligible patients were patients not on dialysis, ESA naïve 
or not at baseline. The primary endpoint was the relative importance according 
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by the patient preference to different characteristics of ESA treatments. Patients 
had to complete a questionnaire at baseline and around 6-month. Questionnaire 
was developed using a CBC analysis method with the following hypothesis: 1) 7 
ESA characteristics; 2) from 2 to 3 levels per characteristics; 3) each possible 
answer includes 1 level for 2 characteristics; 4) 2 choices per question; 5) and 6) 7 
questions per CBC questionnaire. The number of combinations between all 
characteristics and levels was 288, and 20 questionnaires have been generated in 
order to mix all possible treatment characteristics and levels. Patients only had 
to answer one questionnaire and a randomization has been used to obtain equal 
number of respondents for each questionnaire. CBC analysis was planned and 
performed for subgroup of patients already receiving ESA or not. RESULTS: A 
total of 790 patients were included, 609 questionnaires were analyzed at 
baseline. Fifty-five percent of patients were already treated by ESA, among them 
the most important characteristic was the planned frequency of administration 
for 31%, followed by the importance of the treatment efficacy for 20%, the pain at 
injection site for 11%. But when asking a direct question to patient on which 
characteristic was the most important, 82% of them answered treatment 
efficacy, 5% for pain at injection site and frequency of injection. Similar results 
were found for ESA naïve patients. CONCLUSIONS: The CBC analysis revealed 
that frequency of injections is underestimated by patients and should be taken 
into account by physicians when choosing an ESA treatment.  
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ONE MONTH AFTER TREATMENT INITIATION NOCTURIA PATIENTS SLEPT 
SIGNIFICANTLY LONGER AND BETTER ON TREATMENT THAN PLACEBO 
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OBJECTIVES: To explore how fast patients treated for nocturia (waking up  
at night one or more times to void) reported improvement in initial period  
of undisturbed sleep and sleep quality. METHODS: A 3 month randomized, 
controlled, double-blind study at 39 centers in US and Canada comparing 
treatment versus placebo in patients with ≥2 voids/night. The initial period  
of undisturbed sleep was based on patient reported sleep/void diary. Self 
reported sleep quality was assessed by two VAS scales: 1) quality of last night’s 
sleep, and 2) feeling refreshed in the morning. RESULTS: Following 1 week of 
Desmopressin treatment patients on both placebo and drug had an increase in 
undisturbed sleep (women: 81/105 min; men 30/71 min (placebo/treatment, 
respectively)). After 1 month treatment patients slept statistical significantly 
longer (women 95 /131 min, p=0.02; men 56/99 min, p<0.001), increasing to a 3 
month treatment contrast of 49 minutes (women) and 39 minutes (men) and 
with a mean total period of undisturbed sleep of 5.2 hours (women) and 4.3 
hours (men). Patient self reported sleep quality on a 10 point scale increased 
after 1 week (women 1.2 vs. 1.6; men 0.5 vs. 0.7) growing to significant treatment 
difference in women (p= 0.03) and numerical difference in men after 3 months 
(women 1.8 vs. 2.3; men 1.3 vs. 1.7). Self reported feeling of being “refreshed in 
the morning” increased after 1 week (women 1.1 vs. 1.5; men 0.5 vs. 0.7) and was 
statistically significant versus placebo at month 3 (women 1.7 vs. 2.2, p=0.04; 
men 0.85 vs. 1.34, p=0.01). CONCLUSIONS: Treatment increased patients self 
reported initial period of undisturbed sleep already after one week and was 
significantly different from placebo from month 1 and onwards. Patients 
experienced a consequent improvement in sleep quality and feeling refreshed in 
the morning.  
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OBJECTIVES: Traditionally, treatment of nocturia (waking up at night one or 
more times to void) has been focused on a reduction in number of voids. 
However, a serious consequence of nocturia is fragmentation of sleep. Research 
has shown that the initial hours of sleep is fundamental for obtaining the 
necessary amount of slow wave sleep (SWS). METHODS: Data from two 
randomized, placebo-controlled trials (US/Can) with 646 adult patients  
with nocturia (≥2 voids/night determined via 3-day voiding diary) was used. 
Patients were to rate three sleep quality questions on a 10-point visual  
analogue scale during the three months of treatment (baseline, Day 4, Week 1, 
Month 1, 2 and 3): 1) How do you feel right now? 2) Feeling refreshed in the 
morning? and 3) Quality of last night’s sleep? A threshold of 4 hours to time to 
first void (TTFV) (i.e. initial undisturbed sleep) were explored in terms of 
improved scores in the sleep quality questions, by comparing patients in the 
following 4 groups: 1) Poor sleep: TTFV <4 hours at all visits (baseline and post-
baseline); 2) Improved somewhat: Baseline TTFV <4 hours and at least 1 post-
baseline TTFV ≥4 hours; 3) Improved: Baseline TTFV <4 hours, all post-baseline 
TTFV ≥4 hours; and 4) Over threshold at baseline: Baseline TTFV ≥4 hours. 
RESULTS: The change from baseline in all three sleep quality questions were 
statistically and clinically improved for group 2 (Improved somewhat) and even 
further improved for group 3 when comparing with group 1, with significant 
differences already occurring at week 1. The differences widened over the study 
period. The magnitude of improvement was consistently higher for females 
compared to males. CONCLUSIONS: In conclusion, more than 4 hours of 
undisturbed sleep is associated with rapid and clinically meaningful 
improvements in sleep quality for nocturia patients and could be used as a 
future treatment goal.  
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OBJECTIVES: Patient-reported disease burden in Autosomal Dominant Polycystic 
Kidney Disease (ADPKD) has not been rigorously documented. This study 
provides initial evaluation of the psychometric properties of two new ADPKD-
targeted instruments: ADPKD Impact Scale (ADPKD-IS) and ADPKD Urinary 
Impact Scale (ADPKD-UIS). METHODS: US-English versions of ADPKD-IS and 
ADPKD-UIS were administered to 702 adults with ADPKD as part of an 
observational study. Confirmatory factor analysis (CFA) was conducted to test 
the fit of previously developed conceptual frameworks. Next, item response 
theory (IRT) and classical psychometrics were examined, including item- and 
scale-level reliability and convergent validity (with the SF-12v2 and Brief Pain 
Inventory – Short Form (BPI-SF)). RESULTS: CFA results for both instruments 
demonstrated good fit between data and conceptual frameworks (ADPKD-IS 
domains of physical impact, fatigue, and emotional impact and ADPKD-UIS 
domains of urinary urgency burden, urinary frequency burden, and nocturia 
burden): ADPKD-IS = confirmatory fit index (CFI)/nonnormed fit index (NNFI) > 
0.95, root mean square error of approximation (RMSEA) < 0.06; ADPKD-UIS = 
CFI/NNFI > 0.99, RMSEA < 0.08. IRT- and item-level analyses revealed no 
misclassified items with their intended scales or problems with skew or 
inappropriate heterogeneity of variance throughout the response scale. Internal 
consistency reliability for all domains ranged from the mid .80s to mid .90s. 
Convergent validity of the ADPKD-IS/ADPKD-UIS domains was supported by 
correlations with the SF-12 (PCS/MCS) and BPI-SF domains (mid .40s to mid .60s). 
CONCLUSIONS: The ADPKD IS/ADPKD-UIS instruments demonstrated 
prespecified psychometric criteria. Whereas longitudinal evaluation of these 
measures is needed, the current study provides encouraging results for these 
new ADPKD-specific measures of patient burden.  
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OBJECTIVES: To assess the content validity of the Actionable Bladder Symptom 
Screening Tool (ABSST), previously validated in patients with multiple sclerosis 
(MS) associated neurogenic detrusor overactivity (NDO), in women with 
overactive bladder (OAB) and urgency urinary incontinence (UUI). The ABSST is 
an 8-item questionnaire which assesses bladder symptoms along with their 
impact. METHODS: Cognitive interviews were conducted with non-diabetic 
female gynecology patients suffering from OAB and UUI to 1) understand how 
subjects describe experiencing OAB and UUI and, 2) assess subjects’ 
comprehension of the ABSST. Interviews were audio-recorded, transcribed 
verbatim, and analyzed using Atlas.ti. RESULTS: Ten subjects were interviewed; 
6 Caucasian, mean age was 49.2 ± 13.7, and 7 full- or part-time employed. All  
10 subjects had clinician-confirmed and self-reported OAB (average duration 6.9 
± 4.7 years). Mean ABSST score was 4.2 out of 8. Subjects understood the  
5 symptom items (frequencies of urinary urgency, urgency incontinence, 
nocturia, and total micturition, and intensity of urinary urgency) and the 3 
impact items (social limitations, embarrassment, and work limitations) as 
intended including instructions, and response options. Subjects confirmed that 
the symptoms were relevant and important. Although only a few subjects 
spontaneously reported experiencing the symptom impacts, 6 subjects 
acknowledged embarrassment was important and 7 subjects reported 
experiencing work limitations. CONCLUSIONS: Overall, subjects found the 
ABSST items relevant and easy to understand. Participants found the symptom 
items were more relevant than the impact items. Possible explanations may be 
that these gynecology patients are a younger, healthier group compared to the 
MS sample, and have adapted to and coped with their conditions thereby 
lessening the perceived impacts of OAB and UUI. Nonetheless, the ABSST was 
understood well and was reported to be comprehensive and relevant to their 
experiences with OAB and UUI symptoms.  
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OBJECTIVES: Mirabegron, a novel selective beta-3 adrenergic agonist, has 
recently been approved in the United States for the treatment of overactive 
bladder (OAB). This study aimed to assess the impact of mirabegron on Work 
Productivity and Activity Impairment (WPAI) and the associations between WPAI 
outcomes and OAB symptom severity. METHODS: Data were obtained from a 12-
week phase III randomized trial (NCT00662909) comparing mirabegron 50mg and 
placebo for OAB treatment. WPAI outcomes were measured using the WPAI-
Questionnaire for OAB, including employment and total activity impairment 
(TAI) for all patients, and absenteeism, presenteeism and total work productivity 
impairment (TWPI) for employed patients. OAB severity measures included 
